CA2709545C - Topical application and formulation of erythropoietin for skin wound healing - Google Patents

Topical application and formulation of erythropoietin for skin wound healing Download PDF

Info

Publication number
CA2709545C
CA2709545C CA2709545A CA2709545A CA2709545C CA 2709545 C CA2709545 C CA 2709545C CA 2709545 A CA2709545 A CA 2709545A CA 2709545 A CA2709545 A CA 2709545A CA 2709545 C CA2709545 C CA 2709545C
Authority
CA
Canada
Prior art keywords
epo
gelatinous
wound
gel
viscous formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2709545A
Other languages
English (en)
French (fr)
Other versions
CA2709545A1 (en
Inventor
Augustinus Bader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709545A1 publication Critical patent/CA2709545A1/en
Application granted granted Critical
Publication of CA2709545C publication Critical patent/CA2709545C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2709545A 2007-12-28 2008-12-20 Topical application and formulation of erythropoietin for skin wound healing Active CA2709545C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07025167 2007-12-28
EP07025167.3 2007-12-28
PCT/EP2008/010978 WO2009083203A2 (de) 2007-12-28 2008-12-20 Topische anwendung und formulierung von erythropoietin für die wundheilung der haut

Publications (2)

Publication Number Publication Date
CA2709545A1 CA2709545A1 (en) 2009-07-09
CA2709545C true CA2709545C (en) 2013-10-29

Family

ID=40751089

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709545A Active CA2709545C (en) 2007-12-28 2008-12-20 Topical application and formulation of erythropoietin for skin wound healing

Country Status (11)

Country Link
US (1) US9101586B2 (enExample)
EP (1) EP2222327B1 (enExample)
JP (1) JP5553769B2 (enExample)
CN (1) CN101951944B (enExample)
AU (1) AU2008342920B2 (enExample)
BR (1) BRPI0821814A2 (enExample)
CA (1) CA2709545C (enExample)
DK (1) DK2222327T3 (enExample)
ES (1) ES2625145T3 (enExample)
RU (1) RU2465003C2 (enExample)
WO (1) WO2009083203A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110123481A1 (en) 2007-08-16 2011-05-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
EP2590666B1 (en) 2010-07-06 2017-04-26 Augustinus Bader Topical application of erythropoietin for use in the treatment of injuries of the cornea
WO2012031778A1 (de) 2010-09-12 2012-03-15 Augustinus Bader Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
US11446364B2 (en) * 2012-11-14 2022-09-20 Smith & Nephew, Inc. Stable thermolysin hydrogel
WO2014150857A1 (en) 2013-03-15 2014-09-25 Smith & Nephew, Inc. Dissolvable gel-forming film for delivery of active agents
CN105377285B (zh) * 2013-04-30 2020-04-21 南加利福尼亚大学 通过血管紧缩素肽的加速的眼睛损伤的治愈
WO2015075406A1 (en) * 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
CN107427559A (zh) * 2015-09-04 2017-12-01 赛巴纳医药有限公司 局部用红细胞生成素制剂和用其提高伤口愈合的方法及其美容用途
RU2611401C1 (ru) * 2015-10-28 2017-02-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ получения лекарственного средства с эритропоэтином местного действия
EP3391887A4 (en) * 2015-12-16 2019-08-21 Daiichi Sankyo Company, Limited WOUNDS TREATMENT AGENT
PL3538065T3 (pl) 2016-11-10 2023-12-04 Asc Regenity Ltd. Formulacje kosmetyczne do zastosowań miejscowych zawierające cząsteczki pochodzące z erytropoetyny
RU2679446C2 (ru) * 2017-03-16 2019-02-11 Алексей Валерьевич Люндуп Способ лечения синдрома диабетической стопы
GB201720320D0 (en) 2017-12-06 2018-01-17 Univ Of Sussex Tissue repair
RU2754383C1 (ru) * 2020-12-07 2021-09-01 Федеральное Государственное Бюджетное Учреждение "Национальный Медицинский Исследовательский Центр Эндокринологии" Министерства Здравоохранения Российской Федерации (Фгбу "Нмиц Эндокринологии" Минздрава России) Способ лечения неинфицированного послеоперационного раневого дефекта стопы при отсутствии признаков критической ишемии конечности у больных с нейропатической и нейроишемической формой синдрома диабетической стопы
CN112961821B (zh) * 2021-02-24 2023-05-30 四川大学华西医院 三维培养血管内皮细胞的方法
CN115177782B (zh) * 2021-04-02 2023-07-18 诺一迈尔(山东)医学科技有限公司 一种高透气、促愈合的液体创可贴及其制备方法
EP4395797A4 (en) * 2022-06-29 2025-09-03 Biostem Tech Inc MICRONIZED WOUND HEALING COMPOSITIONS PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUES HAVING AN INTACT INTERMEDIATE SPONGE LAYER POSITIONED BETWEEN THEM

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
JP2000507912A (ja) 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
JP2000095678A (ja) * 1998-09-22 2000-04-04 Dai Ichi Kogyo Seiyaku Co Ltd パップ剤用基剤およびそれを含有するパップ剤
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
ES2422881T3 (es) 2002-06-20 2013-09-16 Augustinus Bader Uso de eritropoyetina para la regeneración de tejido in vivo
DE10260873A1 (de) * 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
EP1548031A1 (en) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
WO2005063965A1 (de) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
WO2005070451A1 (en) * 2004-01-22 2005-08-04 Zafena Aktiebolag Pharmaceutical composition comprising non-glycosylated erythropoietin
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
JP2008530230A (ja) 2005-02-16 2008-08-07 アルザ・コーポレーシヨン エリスロポエチンに基づく剤の経皮送達のための装置および方法
AU2006278328A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof

Also Published As

Publication number Publication date
US9101586B2 (en) 2015-08-11
ES2625145T3 (es) 2017-07-18
WO2009083203A3 (de) 2010-02-18
CN101951944A (zh) 2011-01-19
JP5553769B2 (ja) 2014-07-16
EP2222327A2 (de) 2010-09-01
BRPI0821814A2 (pt) 2015-06-16
CA2709545A1 (en) 2009-07-09
AU2008342920A1 (en) 2009-07-09
DK2222327T3 (en) 2017-05-15
US20100278916A1 (en) 2010-11-04
RU2010130890A (ru) 2012-02-10
RU2465003C2 (ru) 2012-10-27
AU2008342920B2 (en) 2014-09-18
WO2009083203A2 (de) 2009-07-09
EP2222327B1 (de) 2017-02-15
CN101951944B (zh) 2015-04-01
JP2011507920A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
CA2709545C (en) Topical application and formulation of erythropoietin for skin wound healing
ES2288024T3 (es) Composiciones de hidrogel para la liberacion controlada en la administracion de factores de crecimiento.
US20230372579A1 (en) Methods for treating wounds
EP2059206B1 (en) Dry wound dressing and drug delivery system
Bhatnagar et al. Delivery systems for platelet derived growth factors in wound healing: A review of recent developments and global patent landscape
BRPI0717734B1 (pt) Método para preparar um pó seco de nanopartículas poliméricas, pó seco e uso do mesmo
JPH04211019A (ja) 創傷治癒促進のためのトロンボスポンデインの使用
Santhan A Comparative Study between Efficacy Of Topical Sucralfate And 5% Povidone Iodine In Chronic Lower Limb Ulcers
CN121081602A (zh) SjP40蛋白的应用、促进皮肤组织修复的组合物及其制备方法、药物制剂
Hrynyk Enhanced burn wound healing through controlled and sustained delivery of bioactive insulin from alginate sponge dressings
IL303383A (en) Compositions and methods for treating wounds
Stegbauer Enhanced wound healing using topical recominant human platelet-derived growth factor
HK1240851A1 (en) Compositions for treating wounds

Legal Events

Date Code Title Description
EEER Examination request